TEV-53408
Phase 1Small molecule
TevaTEV-53408 is one of 27 small molecule programs targeting Vitiligo. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Vitiligo
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Trexall
Jazz PharmaceuticalsApproved
Cosentyx
NovartisApproved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Asmanex
PPerrigo Company
Approved
Elidel
BBausch Health Americas, Inc.
Approved
Adrucil
EElorac, Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Rinvoq
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vitiligo1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TEV-53408. EMBL-EBI & Wellcome Sanger Institute.
- [4]